Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.
Bono M, Fanale D, Incorvaia L, Cancelliere D, Fiorino A, Calò V, Dimino A, Filorizzo C, Corsini LR, Brando C, Madonia G, Cucinella A, Scalia R, Barraco N, Guadagni F, Pedone E, Badalamenti G, Russo A, Bazan V. Bono M, et al. Among authors: guadagni f. ESMO Open. 2021 Aug;6(4):100235. doi: 10.1016/j.esmoop.2021.100235. Epub 2021 Aug 7. ESMO Open. 2021. PMID: 34371384 Free PMC article.
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials.
Santini D, Galvano A, Pantano F, Incorvaia L, Rizzo S, Vincenzi B, Castellana L, Giuliana G, Guadagni F, Toia F, Tonini G, Russo A, Badalamenti G, Bazan V. Santini D, et al. Among authors: guadagni f. Crit Rev Oncol Hematol. 2019 Oct;142:68-75. doi: 10.1016/j.critrevonc.2019.07.013. Epub 2019 Jul 25. Crit Rev Oncol Hematol. 2019. PMID: 31377434
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials.
Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, Cusenza S, Cutaia S, Santini D, Guadagni F, Roselli M, Gori S, Latteri MA, Bazan V, Giulia LM, Russo A. Galvano A, et al. Among authors: guadagni f. J Bone Oncol. 2019 Jul 16;18:100252. doi: 10.1016/j.jbo.2019.100252. eCollection 2019 Oct. J Bone Oncol. 2019. PMID: 31440444 Free PMC article. Review.
Irinotecan or Oxaliplatin: Which is the First Move for the Mate?
Morelli C, Formica V, Riondino S, Russo A, Ferroni P, Guadagni F, Roselli M. Morelli C, et al. Among authors: guadagni f. Curr Med Chem. 2021;28(16):3158-3172. doi: 10.2174/0929867327666201016124950. Curr Med Chem. 2021. PMID: 33069191 Review.
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies.
Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Galvano A, Del Re M, Malapelle U, Chiari R, Conte P, Danesi R, Fassan M, Ferrara R, Genuardi M, Ghiorzo P, Gori S, Guadagni F, Marchetti A, Marchetti P, Midiri M, Normanno N, Passiglia F, Pinto C, Silvestris N, Tallini G, Vatrano S, Vincenzi B, Cinieri S, Beretta G. Russo A, et al. Among authors: guadagni f. Crit Rev Oncol Hematol. 2022 Jan;169:103567. doi: 10.1016/j.critrevonc.2021.103567. Epub 2021 Dec 8. Crit Rev Oncol Hematol. 2022. PMID: 34896250 Review.
BRCA1 and BRCA2 mutations in central and southern Italian patients.
Ottini L, D'Amico C, Noviello C, Lauro S, Lalle M, Fornarini G, Colantuoni OA, Pizzi C, Cortesi E, Carlini S, Guadagni F, Bianco AR, Frati L, Contegiacomo A, Mariani-Costantini R. Ottini L, et al. Among authors: guadagni f. Breast Cancer Res. 2000;2(4):307-10. doi: 10.1186/bcr72. Epub 2000 Mar 31. Breast Cancer Res. 2000. PMID: 11056688 Free PMC article.
265 results